Canopy Growth (CGC) Free Cash Flow (2019 - 2025)
Canopy Growth (CGC) reported Free Cash Flow of -$35.8 million for Q4 2025, down 77.32% on a YoY basis from -$157.7 million in Q4 2024, and down 325.71% sequentially from -$8.4 million in Q2 2025.
Canopy Growth (CGC) Free Cash Flow (2019 - 2025) Analysis & Trends
Canopy Growth (CGC) has 7 years of Free Cash Flow data on file, last reported at -$35.8 million in Q4 2025.
- For the quarter ending Q4 2025, Free Cash Flow fell 77.32% year-over-year to -$35.8 million; the trailing twelve-month figure through Mar 2026 stood at -$44.2 million (up 56.81% YoY), and the FY2026 full-year result was -$50.4 million, up 59.03% from the prior year.
- Free Cash Flow eased to -$35.8 million in Q4 2025, from -$8.4 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $15.1 million in Q1 2023 to a low of -$180.2 million in Q1 2021.
- A 5-year average of -$68.5 million and a median of -$52.6 million in 2022 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow plunged 450.2% in 2021 and jumped 170.38% in 2023, its largest moves.
- Tracing CGC's Free Cash Flow over 5 years: stood at -$133.6 million in 2021, then fell by 9.19% to -$145.8 million in 2022, then jumped by 83.31% to -$24.3 million in 2023, then advanced by 17.11% to -$20.2 million in 2024, then plunged by 77.32% to -$35.8 million in 2025.
- Business Quant data shows CGC's Free Cash Flow at -$35.8 million in Q4 2025, -$8.4 million in Q2 2025, and -$20.2 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -208.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 291.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -373.37 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 363.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 348.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 144.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -38.00 Mn |
| 10 | Canopy Growth | 197.77 Mn | -68.15 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -35.77 Mn |
| Dec 31, 2025 | -35.77 Mn |
| Jun 30, 2025 | -8.40 Mn |
| Jun 30, 2025 | -8.40 Mn |
| Dec 31, 2024 | -20.17 Mn |
| Dec 31, 2024 | -20.17 Mn |
| Sep 30, 2024 | -41.37 Mn |
| Sep 30, 2024 | -41.37 Mn |
| Jun 30, 2024 | -40.72 Mn |
| Jun 30, 2024 | -40.72 Mn |
| Mar 31, 2024 | -16.56 Mn |
| Mar 31, 2024 | -16.56 Mn |
| Dec 31, 2023 | -24.34 Mn |
| Dec 31, 2023 | -24.34 Mn |
| Sep 30, 2023 | -90.85 Mn |
| Sep 30, 2023 | -90.85 Mn |
| Jun 30, 2023 | -80.52 Mn |
| Jun 30, 2023 | -80.52 Mn |
| Mar 31, 2023 | 15.13 Mn |
| Mar 31, 2023 | 15.13 Mn |